DMAC Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 geg. 2024 @ 21:54):

Stats
Dzisiejszy wolumen	7 327.00
Średni wolumen	40 400.00
Kapitalizacja rynkowa	113.89M
EPS	$0 ( 2024-05-20 )
Następna data zysków	( $-0.160 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.00
ATR14	$0.0160 (0.53%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Lorianne Masuoka K.	Buy	285 000	Stock option (right to buy)
2024-01-22	Lorianne Masuoka K.	Buy	0
2024-01-02	Semba Charles Pauling	Buy	9 375	Voting Common Shares, no par value per share
2024-01-02	Kuntz Richard	Buy	14 285	Voting Common Shares, no par value per share
2024-01-02	Pilnik Richard D.	Buy	30 357	Voting Common Shares, no par value per share

INSIDER POWER
54.04
Last 91 transactions
Buy: 8 059 792 \| Sell: 2 870 847

DiaMedica Therapeutics Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

DiaMedica Therapeutics Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-30 000.00 (0.00 %)
EPS:	$-0.600

FY	2023
Przychody:	$0
Zysk brutto:	$-30 000.00 (0.00 %)
EPS:	$-0.600

FY	2022
Przychody:	$0
Zysk brutto:	$-25 000.00 (0.00 %)
EPS:	$-0.520

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.650

Financial Reports:

No articles found.

DiaMedica Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.